跳到正文
原文
Medical Xpress·· 2026-10-06精选AI 评分75

ACP 新指南推荐激素治疗作为绝经期血管舒缩症状一线治疗

Hormonal therapy recommended as a first-line treatment for menopausal vasomotor symptoms

AI 导读

美国内科医师学会(ACP)在《Annals of Internal Medicine》发布临床指南,推荐有子宫的女性使用雌激素联合孕激素、无子宫者使用雌激素单药,作为围绝经期和绝经后女性血管舒缩症状(潮热与盗汗)的一线治疗。

推荐理由

ACP 新指南把雌激素列为绝经期潮热盗汗一线,并给出存在禁忌时的二、三线替代顺序,便于对照用药。

正文
menopausal
Credit: Timur Weber from Pexels

The American College of Physicians (ACP) recommends estrogen in combination with progestogen (for females with a uterus) or estrogen monotherapy (for females without a uterus) as first-line treatment for perimenopausal and postmenopausal females experiencing menopausal vasomotor symptoms (VMS), which consist of hot flashes and night sweats. ACP's new clinical guideline is published in Annals of Internal Medicine.

VMS are the most common symptoms associated with menopause and affect up to 80% of females. Beginning in perimenopause, declining and fluctuating reproductive hormone levels can lead to VMS and other symptoms, including sleep disturbance, weight fluctuations, anxiety, depression and genitourinary symptoms. VMS can persist into postmenopausal years, and their frequency and severity can disrupt daily activities and affect quality of life.

For females seeking treatment for VMS, ACP concluded that estrogen in combination with progestogen and estrogen monotherapy had the most favorable benefits compared with harms. For females who have contraindications to or do not tolerate estrogen therapy, ACP suggests physicians use an SNRI (desvenlafaxine or venlafaxine) as second-line treatment, or an SSRI (escitalopram or paroxetine), gabapentin, or an NKra (elinzanetant or fezolinetant) as third-line treatment. ACP encourages physicians to ask their patients about their experience with menopausal VMS, as many females may not initiate these discussions on their own.

ACP emphasizes that when selecting a treatment for VMS, clinicians should use an informed decision-making approach and discuss benefits, harms, contraindications, comorbid conditions, values and preferences, financial burden, and access to and availability of treatments.

Publication details

Pharmacologic Treatments for Females With Menopausal Vasomotor Symptoms: A Clinical Guideline From the American College of Physicians, Annals of Internal Medicine (2026). DOI: 10.7326/ANNALS-26-01205

Journal information: Annals of Internal Medicine

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Hormonal therapy recommended as a first-line treatment for menopausal vasomotor symptoms (2026, October 5) retrieved 5 October 2026 from https://medicalxpress.com/news/2026-10-hormonal-therapy-line-treatment-menopausal.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com